{"id":3906,"date":"2017-04-25T08:30:54","date_gmt":"2017-04-25T08:30:54","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=3906"},"modified":"2017-04-23T18:47:56","modified_gmt":"2017-04-23T18:47:56","slug":"bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/","title":{"rendered":"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie"},"content":{"rendered":"<p>AMB 2017, 51, 29 Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie Fazit: Die lokale Anwendung eines hochpotenten Glukokortikosteroids ist die beste Behandlungsoption beim bull\u00f6sen kutanen Pemphigoid. Sind jedoch gro\u00dfe Hautareale betroffen, ist h\u00e4ufig (zus\u00e4tzlich) eine systemische Therapie mit einem Glukokortikosteroid notwendig. Bei diesen Patienten war in dieser Studie eine initiale Behandlung mit Doxycyclin nach [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2017, 51, 29 Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie Fazit: Die lokale Anwendung eines hochpotenten Glukokortikosteroids ist die beste Behandlungsoption beim bull\u00f6sen kutanen Pemphigoid. Sind jedoch gro\u00dfe Hautareale betroffen, ist h\u00e4ufig (zus\u00e4tzlich) eine systemische Therapie mit einem Glukokortikosteroid notwendig. Bei diesen Patienten war in dieser Studie eine initiale Behandlung mit Doxycyclin nach [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[2642,2641,1206,1246,2079,434,2640,435,436],"class_list":["post-3906","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-blister-studie","tag-bulloeses-pemphigoid","tag-doxycyclin","tag-glukokortikoide","tag-glukokortikosteroide","tag-kortikosteroide","tag-pemphigoid","tag-prednisolon","tag-prednison"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie<\/title>\n<meta name=\"description\" content=\"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie\" \/>\n<meta property=\"og:description\" content=\"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2017-04-25T08:30:54+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2016\/11\/10386263_531671643625514_8318982858760860679_n1.jpg\" \/>\n<meta name=\"author\" content=\"Hiwot\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hiwot\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\\\/\"},\"author\":{\"name\":\"Hiwot\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"headline\":\"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie\",\"datePublished\":\"2017-04-25T08:30:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\\\/\"},\"wordCount\":254,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"BLISTER-Studie\",\"Bull\u00f6ses Pemphigoid\",\"Doxycyclin\",\"Glukokortikoide\",\"Glukokortikosteroide\",\"Kortikosteroide\",\"Pemphigoid\",\"Prednisolon\",\"Prednison\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\\\/\",\"name\":\"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2017-04-25T08:30:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"description\":\"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\",\"name\":\"Hiwot\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"caption\":\"Hiwot\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie","description":"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/","og_locale":"de_DE","og_type":"article","og_title":"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie","og_description":"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2017-04-25T08:30:54+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2016\/11\/10386263_531671643625514_8318982858760860679_n1.jpg","type":"","width":"","height":""}],"author":"Hiwot","twitter_misc":{"Verfasst von":"Hiwot","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/"},"author":{"name":"Hiwot","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"headline":"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie","datePublished":"2017-04-25T08:30:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/"},"wordCount":254,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["BLISTER-Studie","Bull\u00f6ses Pemphigoid","Doxycyclin","Glukokortikoide","Glukokortikosteroide","Kortikosteroide","Pemphigoid","Prednisolon","Prednison"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/","name":"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2017-04-25T08:30:54+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"description":"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/bulloeses-pemphigoid-doxycyclin-versus-prednisolon-als-primaere-therapie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Bull\u00f6ses Pemphigoid: Doxycyclin versus Prednisolon als prim\u00e4re Therapie"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c","name":"Hiwot","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","caption":"Hiwot"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=3906"}],"version-history":[{"count":3,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3906\/revisions"}],"predecessor-version":[{"id":3909,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3906\/revisions\/3909"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=3906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=3906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=3906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}